The [PSI+] prion is a folded in-register parallel β-sheet amyloid (filamentous polymer) of Sup35p, a subunit of the translation termination factor. Our searches for anti-prion systems led to our finding that certain soluble inositol polyphosphates (IPs) are important for the propagation of the [PSI+] prion. The IPs affect a wide range of processes, including mRNA export, telomere length, phosphate and polyphosphate metabolism, energy regulation, transcription and translation. We found that 5-diphosphoinositol tetra(or penta)kisphosphate or inositol hexakisphosphate could support [PSI+] prion propagation, and 1-diphosphoinositol pentakisphosphate appears to inhibit the process.
Yeast prions were originally viewed as a model for the mammalian transmissible spongiform encephalopathies, particularly the Mad Cow disease epidemic in the UK at that time (Wickner 1994) . Now there is increasing evidence that most of the common human amyloidoses have prion-like aspects, and in some cases may be frankly infectious (Jaunmuktane et al. 2015; Junker and Walker 2011; Kraus et al. 2013) , so the importance of the yeast model is even greater.
While nearly 10 yeast and fungal prions have been described [reviewed in (Wickner et al. 2015) ], the [PSI+] and [URE3] prions, self-propagating amyloids of Sup35p and Ure2p (the latter a regulator of nitrogen catabolism) have been most intensively investigated. The folded inregister parallel β-sheet architecture, shown for several, can explain how these amyloids can self-template their structures, and so how they can act as genes composed of protein, with multiple alleles (called prion variants in yeast or prion strains in mammals) [(Fig. 1, (Gorkovskiy et al. 2014; Shewmaker et al. 2006; Wickner et al. 2015) ].
Overproduction or deficiency of many chaperones and other cell components have been found to result in prion loss (e.g. Chernoff et al. 1995; Higurashi et al. 2008; Kryndushkin et al. 2008; Sharma and Masison 2008; Troisi et al. 2015) . Deletion or overexpression of a protein can efficiently eliminate a prion by very indirect means, or, although direct, by producing a condition that does not occur in the wild. But recently we have proposed a new 'definition' of anti-prion system/component, namely a protein that eliminates a prion when expressed at its normal level. With this approach several anti-prion systems have been shown, starting with proteins whose curing activity was first shown by overproduction. Hsp104 overproduction cures the [PSI+] prion (Chernoff et al. 1995) , and Btn2p or Cur1p overproduction cure the [URE3] prion (Kryndushkin et al. 2008) . But most of the prion variants isolated in strains lacking these curing activities are cured by simply restoring the normal level of the active protein (Gorkovskiy et al. 2017; Wickner et al. 2014) . In effect, what has been discovered is a large array of [PSI+] and [URE3] variants that would normally never appear because the normal levels of the Hsp104 or Btn2p or Cur1p would cure them as they arise.
In a general screen for anti-prion systems using the yeast knockout collection, an siw14Δ mutation was found to allow many variants of [PSI+] to propagate that could not propagate in SIW14 + cells ). However, overexpression of Siw14p did not cure any [PSI+] variants isolated in normal cells. Since Siw14p was recently identified as a pyrophosphatase specific for the 5-pyrophosphate-inositol pentakisphosphate (5PP-IP 5 , see Fig. 2 ) (Steidle et al. 2016) , it was suspected that some inositol poly/pyro-phosphates promote prion propagation propagation, and presumably 5PP-IP 5 can also fulfill this function (Fig. 2) . . Inositol poly/pyro-phosphates are known to have a wide array of functions (Table 1) , but none of these functions immediately explain their requirement for [PSI+] prion propagation. The need for inositol pyrophosphates for the 'environmental stress response', was the most suggestive, but the ability of kcs1Δ vip1Δ mutants (that make no inositol pyrophosphates ) to support [PSI+] indicates that the prion is supported by another IP function . These kcs1Δ vip1Δ mutants do make inositol hexakisphosphate (IP 6 ), but kcs1Δ ipk1Δ mutants do not make IP 6 and do not support [PSI+] , implicating IP 6 as another species capable of helping [PSI+] propagate ). In spite of being able to make IP 6 , kcs1Δ ddp1Δ mutants (see Fig. 2 ) lose [PSI+] . These mutants make elevated levels of 1-disphosphoinositol pentakisphosphate , suggesting that this compound may inhibit [PSI+] propagation .
These experiments have revealed an unexpected level of control over prion propagation. However, the mechanism by which these inositol poly/pyro-phosphates exert their positive and negative control is unknown. The inositol Fig. 1 Conformational templating mechanism based on the folded inregister parallel β-sheet architecture of yeast prion amyloids (Wickner et al. 2015) . Favorable interactions between identical amino acid side chains (hydrogen bonds or hydrophobic interactions) maintain the in-register architecture, and drive a monomer joining the end of an amyloid filament to acquire turns/folds at the same locations as those of molecules already in the filament. This conformational templating, analogous to DNA's sequence templating, allows these proteins to be genes (Wickner et al. 2015) . Different prion variants (with the same protein sequence) are hypothesized to have the folds/turns at different locations Fig. 2 Biosynthetic pathways of the soluble inositol poly/pyro-phosphates (IPs) [reviewed in Saiardi et al. (2017) , Tsui and York (2010) ]. IP 6 and 5PP-IP 4 , and probably 5PP-IP 5 , are capable of helping [PSI+] propagate (green arrows), and 1PP-IP 5 may inhibit [PSI+] propagation (red blockage symbol) pyrophosphates contain high energy pyrophosphate bonds and have been shown able to pyrophosphorylate proteins at certain amino acid residues that are already monophosphorylated (Saiardi et al. 2004) . It is conceivable that this activity is involved in supporting [PSI+] by direct modification of Sup35p, but the ability of IP 6 , lacking pyrophosphates, to support [PSI+] argues against this idea. IPs are very highly charged molecules and can bind to positively charged regions on certain proteins (e.g., Macbeth et al. 2005) , but the prion domain of Sup35p, the part that actually forms the amyloid structure, has very few charged residues, including only two arginines and one lysine in the 123 residues.
It is quite possible that the IPs are acting on some other protein to augment, diminish or qualitatively change its activity in such a way that [PSI+] propagation is allowed. Solid resins with IP 6 or 5PP-IP 5 covalently attached were designed and used to purify proteins from Saccharomyces cerevisiae that had specific affinity for one of these molecules . Note that these are two of the molecules that we found were each sufficient to support [PSI+] propagation. Among the ~ 40 proteins that bound to both resins were Ssb1 and Ssb2, ribosome-associated Hsp70 chaperones; Hsp26p, a small heat shock protein; and Sse1p, an Hsp70 family member with nucleotide exchange activity. The Ssb proteins (Chernoff and Kiktev 2016; Chernoff et al. 1999 ) and Sse1p (Fan et al. 2007; Kryndushkin and Wickner 2007 ) are known to affect [PSI+] generation and propagation, but preliminary efforts to prove these as targets of the IPs have not yet succeeded. Whatever the mechanism, Siw14p appears to be working by limiting the levels of certain inositol pyrophosphates, preventing the propagation of a group of [PSI+] variants that need a high level of these compounds.
This work opens a new avenue for investigation of antiprion/anti-amyloid modalities. Do human amyloidoses involve IPs in some way? The IP biosynthetic pathways in yeast and humans are very similar, and most pathogenic human amyloids studied have, like the yeast prions, the folded in-register parallel β-sheet architecture [reviewed by Tycko (2014) , Tycko and Wickner (2013) ]. Of course, even [URE3] is not affected by IP deficiency, so there need not be direct carry-over of these results to mammals. Nonetheless, these results again highlight the familiar theme that studies of yeast, rapidly and cheaply carried out, can form the basis for the understanding of human disease processes. Shen et al. (2003) , Steger et al. (2003) 
